Publication date: Jul 18, 2024
The current document is an update of the recommendations of the Sociedad Argentina de PediatrcEDa based on a bibliographic review of publication from recent years on the use of the monoclonal antibody against respiratory syncytial virus (RSV), palivizumab, in groups of patients at high risk of developing severe respiratory infection. The continuing relevance of RSV as a causative agent of acute lower respiratory infections and hospitalizations are highlighted. The epidemiology of RSV in the country after the COVID-19 pandemic was reviewed. The risk groups in which the use of palivizumab is indicated according to the underlying condition were discussed, as well as aspects of its dosing and future therapeutic options.
| Concepts | Keywords |
|---|---|
| Antibody | disease prevention |
| Argentina | monoclonal antibodies |
| Hospitalizations | mortality |
| Pandemic | palivizumab |
| respiratory syncytial virus |
Semantics
| Type | Source | Name |
|---|---|---|
| drug | DRUGBANK | Palivizumab |
| disease | VO | document |
| disease | VO | publication |
| disease | VO | Respiratory syncytial virus |
| disease | MESH | infection |
| disease | MESH | respiratory infections |
| disease | IDO | country |
| disease | MESH | COVID-19 pandemic |